statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	496
SG - Singapore	81
CN - Cina	80
HK - Hong Kong	59
IT - Italia	48
BR - Brasile	41
VN - Vietnam	35
DE - Germania	34
BD - Bangladesh	31
GB - Regno Unito	31
RU - Federazione Russa	13
FI - Finlandia	12
ID - Indonesia	12
KR - Corea	12
IN - India	11
FR - Francia	10
CA - Canada	8
AR - Argentina	7
LT - Lituania	7
MX - Messico	7
PL - Polonia	6
NL - Olanda	5
SE - Svezia	5
UA - Ucraina	4
AE - Emirati Arabi Uniti	3
ES - Italia	3
ZA - Sudafrica	3
AT - Austria	2
EC - Ecuador	2
IQ - Iraq	2
PK - Pakistan	2
SA - Arabia Saudita	2
TR - Turchia	2
AL - Albania	1
AO - Angola	1
BE - Belgio	1
BG - Bulgaria	1
BO - Bolivia	1
CO - Colombia	1
CZ - Repubblica Ceca	1
EE - Estonia	1
EG - Egitto	1
IL - Israele	1
JO - Giordania	1
JP - Giappone	1
KW - Kuwait	1
KZ - Kazakistan	1
LV - Lettonia	1
MA - Marocco	1
MY - Malesia	1
NG - Nigeria	1
PH - Filippine	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TT - Trinidad e Tobago	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.102

Nome	#
New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting	225
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables	219
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models)	188
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1	173
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment	151
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations	141
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients	15
Totale	1.112

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	2	0	0	0	0	0	0	0	0	0	0	0	2
2021/2022	16	2	1	0	3	0	0	0	2	2	2	2	2
2022/2023	36	1	3	3	2	3	2	0	2	4	8	1	7
2023/2024	115	2	6	10	15	22	8	17	12	2	4	6	11
2024/2025	271	3	3	3	16	55	44	19	6	43	19	20	40
2025/2026	590	52	18	33	46	95	23	60	19	80	48	85	31
Totale													1.112